Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

One Company Poised To Flood US Market With Generic HIV Medications

By Meagan Parrish | December 5, 2017

Later this month, several key patents for HIV medications are set to expire. The sudden opening up of the market could be a boon for companies ready to flood the US market with billions of generic HIV pills.

Recently, Bloomberg profiled one such company in India called Laurus Labs Ltd. With a manufacturing facility the size of 35 football fields, the company is hoping to capitalize on its ability to crank out several key compounds used in HIV drugs.

The big patent expirations in the market will be Bristol-Myers Squibb Co.’s Sustiva and Gilead Sciences’ Viread. Laurus already has a hold on 66 percent of the global market for the chemical used in Sustiva — efavirenz — and on 33 percent of the market for tenofovir, the chemical name for Viread.  

With the U.S. market now nearly open for the medications, analysts predict that the company’s revenue will jump $279 million in the current fiscal year to $339 million.

The roughly 1.1 million HIV patients in the U.S. typically take a combination of medications to treat the illness. Despite the potential to tap into this market with generics, Bloomberg notes that companies like Gilead, which rakes in $2.6 billion from HIV drugs, have already begun switching patients to newer medications that are still under patent protection.

And because HIV are often sheltered from the cost of these drugs by various assistance programs, they may be less inclined to demand cheaper generic alternatives.

Nevertheless, Laurus is reportedly gearing up to produce as many as 5 billion tablets of HIV drugs per year, pending U.S. regulatory approval.  

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards